Product class: Authorized package
Medicinal product class: For human use
Package code: 1856101
Name of medicinal product: ABIRATERONE KRKA
Active substances:
Estonian, English, Latin
ATC code: L02BX03
Dosage form: film-coated tablet
Route of administration: oral use
Strengh: 500mg
Amount in package: 56TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Abiraterone Krka is indicated with prednisone or prednisolone for: - the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1) - the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1) - the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxelbased chemotherapy regimen.
Safety features: Yes
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Last imported to Estonia: Never imported to Estonia
Marketing authorization holder: KRKA d.d. Novo mesto 
Marketing authorization number: EU/1/21/1553 
Marketing authorization issued on: 24 June 2021 
Marketing authorization expires on: 28 June 2026 
Marketing authorization procedure type: Centralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: 11 August 2021
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription